Werewolf Therapeutics, Inc. (HOWL) Misses Q1 EPS by 5c

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q1 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $740 thousand versus the consensus estimate of $1.82 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• UBS Reiterates Buy Rating on Dutch Bros Inc. (BROS): 'One of Strongest Growth Stories in Restaurants'
• 'We expect salesforce.com (CRM) to capture a meaningful share of next-gen agentic workflows': Cantor